Mirum's liver infection drug lowers virus levels in late-stage study
MIRM•Mirum said its experimental hepatitis drug brelovitug met the main goal of a late-stage study, with 56% and 45% of patients in two dose groups achieving reduced hepatitis D virus levels and normal liver enzyme levels at 24 weeks, versus 0% in the delayed-treatment group.
1. Study results
Mirum said brelovitug, an experimental monoclonal antibody, met the main goal of a late-stage study in patients with chronic hepatitis delta virus. At 24 weeks, 56% of patients given 300 milligrams and 45% given 900 milligrams achieved a reduction in hepatitis D virus levels and normal liver enzyme levels, compared with 0% in the delayed-treatment group.
2. Safety and next steps
Mirum said the drug was well tolerated across dose groups, with a safety profile consistent with previously reported data. Full study results will be presented at an upcoming medical congress, and the company expects to submit a marketing application to the U.S. FDA in the first half of 2027.
